NeuroMab™ Anti-CD133 BBB Shuttle Antibody(NRZP-1022-ZP3378)

Figure 1 shows the binding of recombinant antibodies to WERI-Rb-1 cells.

The dotted-line histograms show the staining results obtained with the negative control mouse IgG antibody (5 μg/mL). The black-filled histograms show the staining results obtained with (a) the recombinant IgG2a antibody (5 μg/mL), and (b) the positive control hybridoma-produced IgG1 antibody (5 μg/mL).

Figure 2 shows the induction of cytotoxicity by hybridoma-produced and recombinant antibodies; (a) CDC activity and (b) ADCC activity. Recombinant IgG2a antibody has CDC activity. The ability to induce ADCC was not observed in mouse IgG1 and IgG2a antibodies.

Figure 3 shows the binding of human chimeric antibodies to WERI-Rb-1 cells.

The dotted-line histogram shows the staining results obtained with the negative control human IgG antibody. The black-filled histogram shows the staining results obtained with the recombinant chimeric antibody.

Figure 4 shows that human chimeric antibodies induce ADCC activity in WERI-Rb-1 cells.

Figure 5 shows the induction of ADCC activity by human chimeric antibodies in HuH7 cells.

Figure 6 shows the binding ability of humanized antibodies comprising h133H/h133La to antigen-expressing WERI-Rb-1 cells.

The h133H/h133La-comprising humanized antibody binds to WERI-Rb-1 cells in a dose-dependent manner.

Figure 7 shows the results of comparing the binding activities of antibodies derived from combinations of H chains and L chains. Antibodies comprising humanized L chains have reduced binding activity.

Figure 8 shows the results of comparison of binding activities of hybrid L1 chain and hybrid L2 chain antibodies superimposed on the combination of Figure 7 . 7. The antigen-binding activity of the hybrid L1 chain antibody is equivalent to that of the chimeric L chain.

Figure 9 shows the binding activity of humanized L-chain modified antibodies.

Figure 10 shows the binding activity of humanized L chain modified antibodies.